Sterling Pharma Solutions
Mark A. Millar has a diverse work experience in the pharmaceutical industry. Mark A. is currently the Vice President of Global Commercial Operations at Sterling Pharma Solutions, a role they have held since August 2023. Prior to this, they served as the Senior Director of Global Commercial Operations at the same company from September 2020 to August 2023.
Before joining Sterling Pharma Solutions, Mark was a Board Member at BioForward, Inc. from January 2020 to December 2022.
Their previous experience also includes roles at Alcami Corporation, where they served as the Senior Director of API Commercial Operations from April to September 2020. Mark A. also held the position of Director and BU Head of API from June 2017 to March 2020, and Commercial Development Director of API from September 2016 to May 2017.
Mark spent some time at AMRI (Albany Molecular Research Inc.) as the Director of Business Development from January 2015 to September 2016.
Prior to joining AMRI, Mark held several positions at Cedarburg Pharmaceuticals, a division of AMRI. Mark A. served as the Director of Operations from May to December 2014, Director of Project Management from January 2008 to December 2014, and Analytical Chemist from an unspecified time in 2007 to 2008.
Mark began their career at Kleen Test Products as a Microbiology Specialist from September 2004 to September 2006.
Mark A. Millar earned a Bachelors degree in Environmental Science from Royal Roads University, where they studied from 2002 to 2004. In addition, they have obtained the Project Management Professional (PMP) certification from The Project Management Institute (PMI).
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities